Lifileucel
Bone Sarcoma
M.D. Anderson Cancer CenterCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Bone Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Essen Biotech | Phase 2 | BB |
Fludarabine Essen Biotech | Phase 2 | B |
Nivolumab M.D. Anderson Cancer Center | Phase 2 | CCC |
TEONANACATL University Health Network, Toronto | Phase 2 | CCC |
Ipilimumab M.D. Anderson Cancer Center | Phase 2 | CCC |
View all 12 →
Same molecule, other indications
Lifileucel is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →